ReviewSeminars in oncology2008
Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.
Review in Seminars in oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 95 citations in OpenAlex.
- RAPTOR Silencing Inhibits Head and Neck Squamous Cell Carcinoma Progression via Regulation of S100A8/A9 and Urokinase Plasminogen Activator.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Unveiling the Mechanisms Underlying the Immunotherapeutic Potential of Gene-miRNA and Drugs in Head and Neck Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma.Oral oncology · 2022Article
- Effect of PAIP1 on the metastatic potential and prognostic significance in oral squamous cell carcinoma.International journal of oral science · 2022Article
- Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Loss of CPAP causes sustained EGFR signaling and epithelial-mesenchymal transition in oral cancer.Oncotarget · 2021Article
- Article
- Comprehensive review of targeted therapy for colorectal cancer.Signal transduction and targeted therapy · 2020Review
- Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.Journal of hematology & oncology · 2019Article
- Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.Expert opinion on investigational drugs · 2019Review
- Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives.Cancers · 2019Review
- Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits.Current treatment options in oncology · 2018Review
- ΔNp63γ/SRC/Slug Signaling Axis Promotes Epithelial-to-Mesenchymal Transition in Squamous Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas.Cancer biology & therapy · 2018Article
- Review
- Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.OncoTargets and therapy · 2016Review
- 4-Hydroxynonenal activates Src through a non-canonical pathway that involves EGFR/PTP1B.Free radical biology & medicine · 2015Article
- Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.Oncotarget · 2015Article
- HPV in oropharyngeal cancer: the basics to know in clinical practice.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases (RTKs), is highly expressed in head and neck squamous cell carcinoma (HNSCC) where increased EGFR expression levels in tumors are associated with decreased survival. HNSCC patient responses to EGFR-targeted monotherapies in clinical trials, though significant, have been limited. Tumor signaling pathway components that work in cooperation with EGFR or provide compensation for the loss of EGFR-initiated signaling will be ideal targets for therapies to be used in combination with EGFR-targeted agents. Based on the current understanding of molecular signaling pathways and available agents, ErbB family-targeted and Src family-targeted agents represent strategies for further exploration. Here, we discuss agents targeting ErbB and Src family kinases in clinical development, provide an overview of completed and ongoing clinical trials, and outline a molecular rationale for combining ErbB- and Src-targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.